Unmet needs in modern vaccinology
The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kawai, T., & Akira, S. (2007) · Seminars in Immunology · doi:10.1016/j.smim.2006.12.004 · Cited by 1,404
Kool, M., Soullié, T., van Nimwegen, M., Willart, M. A. M., Muskens, F., Jung, S., Hoogsteden, H. C., Hammad, H., & Lambrecht, B. N. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071087 · Cited by 993
The aging of the immune system
Weiskopf, D., Weinberger, B., & Grubeck-Loebenstein, B. (2009) · Transplant International · doi:10.1111/j.1432-2277.2009.00927.x · Cited by 908
Immunosenescence: emerging challenges for an ageing population
Aw, D., Silva, A. B., & Palmer, D. B. (2007) · Immunology · doi:10.1111/j.1365-2567.2007.02555.x · Cited by 880
Stoute, J. A., Slaoui, M., Heppner, D. G., Momin, P., Kester, K. E., Desmons, P., Wellde, B. T., Garçon, N., Krzych, U., Marchand, M., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199701093360202 · Cited by 870
Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes
Stanberry, L. R., Spruance, S. L., Cunningham, A. L., Bernstein, D. I., Mindel, A., Sacks, S., Tyring, S., Aoki, F. Y., Slaoui, M., Denis, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011915 · Cited by 794
Didierlaurent, A. M., Morel, S., Lockman, L., Giannini, S. L., Bisteau, M., Carlsen, H., Kielland, A., Vosters, O., Vanderheyde, N., Schiavetti, F., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901474 · Cited by 758
Alonso, P. L., Sacarlal, J., Aponte, J. J., Leach, A., Macete, E., Milman, J., Mandomando, I., Spiessens, B., Guinovart, C., Espasa, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17223-1 · Cited by 752
New horizons in adjuvants for vaccine development
Reed, S. G., Bertholet, S., Coler, R. N., & Friede, M. (2009) · Trends in Immunology · doi:10.1016/j.it.2008.09.006 · Cited by 618
New horizons in adjuvants for vaccine development
Reed, S. G., Tomai, M., & Gale, M. J. (2020) · Current Opinion in Immunology · doi:10.1016/j.coi.2020.08.008 · Cited by 554
Bojang, K. A., Milligan, P. J., Pinder, M., Vigneron, L., Alloueche, A., Kester, K. E., Ballou, W. R., Conway, D. J., Reece, W. H., Gothard, P., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06957-4 · Cited by 528
Kester, K. E., Cummings, J. F., Ofori‐Anyinam, O., Ockenhouse, C. F., Krzych, U., Moris, P., Schwenk, R., Nielsen, R. A., Debebe, Z., Pinelis, E., et al. (2009) · The Journal of Infectious Diseases · doi:10.1086/600120 · Cited by 524
Leroux-Roels, I., Borkowski, A., Vanwolleghem, T., Dramé, M., Clement, F., Hons, E., Devaster, J.-M., & Leroux-Roels, G. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61297-5 · Cited by 498
Self-citationAguilar, J. C., & Rodríguez, E. G. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.01.111 · Cited by 494
GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives
Garçon, N., Chomez, P., & Van Mechelen, M. (2007) · Expert Review of Vaccines · doi:10.1586/14760584.6.5.723 · Cited by 476
Efficacy of RTS,S/AS01E Vaccine against Malaria in Children 5 to 17 Months of Age
Bejon, P., Lusingu, J., Olotu, A., Leach, A., Lievens, M., Vekemans, J., Mshamu, S., Lang, T., Gould, J., Dubois, M.-C., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807381 · Cited by 417
Alonso, P. L., Sacarlal, J., Aponte, J. J., Leach, A., Macete, E., Aide, P., Sigauque, B., Milman, J., Mandomando, I., Bassat, Q., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67669-6 · Cited by 412
Aluminium adjuvants—in retrospect and prospect
Lindblad, E. B. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.03.032 · Cited by 362
Mechanisms of stimulation of the immune response by aluminum adjuvants
HogenEsch, H. (2002) · Vaccine · doi:10.1016/s0264-410x(02)00169-x · Cited by 354
Mechanism of action of clinically approved adjuvants
Lambrecht, B. N., Kool, M., Willart, M. A., & Hammad, H. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.01.004 · Cited by 354
The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine
Podda, A. (2001) · Vaccine · doi:10.1016/s0264-410x(00)00499-0 · Cited by 333
Skeiky, Y. A. W., Alderson, M. R., Ovendale, P. J., Guderian, J. A., Brandt, L., Dillon, D. C., Campos-Neto, A., Lobet, Y., Dalemans, W., Orme, I. M., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.12.7618 · Cited by 313
Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines
Aucouturier, J., Dupuis, L., Deville, S., Ascarateil, S., & Ganne, V (2002) · Expert Review of Vaccines · doi:10.1586/14760584.1.1.111 · Cited by 308
Monophosphoryl lipid A as an adjuvant. Past experiences and new directions.
Ulrich, J. T., & Myers, K. R. (1995) · PubMed · Cited by 301
Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro
Morefield, G. L., Sokolovska, A., Jiang, D., HogenEsch, H., Robinson, J. P., & Hem, S. L. (2005) · Vaccine · doi:10.1016/j.vaccine.2004.07.050 · Cited by 293
Eleven years of Inflexal® V—a virosomal adjuvanted influenza vaccine
Herzog, C., Hartmann, K., Künzi, V., Kürsteiner, O., Mischler, R., Lazar, H., & Glück, R. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.05.029 · Cited by 292
Aponte, J. J., Aide, P., Renom, M., Mandomando, I., Bassat, Q., Sacarlal, J., Manaca, M. N., Lafuente, S., Barbosa, A., Leach, A., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61542-6 · Cited by 279
Enhancement of antigen-specific immunity via the TLR4 ligands MPL™ adjuvant and Ribi.529
Evans, J. T., Cluff, C. W., Johnson, D. A., Lacy, M. J., Persing, D. H., & Baldridge, J. R. (2003) · Expert Review of Vaccines · doi:10.1586/14760584.2.2.219 · Cited by 243
(How) do aluminium adjuvants work?
BREWER, J. (2006) · Immunology Letters · doi:10.1016/j.imlet.2005.08.002 · Cited by 236
Sun, H.-X., Xie, Y., & Ye, Y.-P. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.05.032 · Cited by 235
The aging of the immune system
Grubeck-Loebenstein, B., & Wick, G. (2002) · Advances in Immunology · doi:10.1016/s0065-2776(02)80017-7 · Cited by 234
Epaxal®: a virosomal vaccine to prevent hepatitis A infection
Bovier, P. A. (2008) · Expert Review of Vaccines · doi:10.1586/14760584.7.8.1141 · Cited by 233
Monophosphoryl Lipid A as an Adjuvant: Past Experiences and New Directions
Ulrich, J. T., & Myers, K. R. (1995) · Pharmaceutical Biotechnology · doi:10.1007/978-1-4615-1823-5_21 · Cited by 222
Chiew Tong, N. K., Beran, J., Kee, S. A., Miguel, J. L., SanNchez, C., Bayas, J. M., Vilella, A., De Juanes, J. R., Arrazola, P., Calbo-Torrecillas, F., et al. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00689.x · Cited by 219
Mechanism of action of licensed vaccine adjuvants
Tritto, E., Mosca, F., & De Gregorio, E. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.01.084 · Cited by 213
Moser, M., & Leo, O. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.07.022 · Cited by 206
Challenges for vaccination in the elderly
Aspinall, R., Del Giudice, G., Effros, R. B., Grubeck-Loebenstein, B., & Sambhara, S. (2007) · Immunity & Ageing · doi:10.1186/1742-4933-4-9 · Cited by 204
Principles of vaccine design—Lessons from nature
Zepp, F. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.07.020 · Cited by 200
Vinageras, E. N., de la Torre, A., Rodríguez, M. O., Ferrer, M. C., Bravo, I., del Pino, M. M., Abreu, D. A., Brooks, S. A., Rives, R., del Castillo Carrillo, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5980 · Cited by 199
New hepatitis B vaccine formulated with an improved adjuvant system
Kundi, M. (2007) · Expert Review of Vaccines · doi:10.1586/14760584.6.2.133 · Cited by 193
Immunosenescence: Role and measurement in influenza vaccine response among the elderly
Targonski, P. V., Jacobson, R. M., & Poland, G. A. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.01.025 · Cited by 186
Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly
De Donato, S., Granoff, D., Minutello, M., Lecchi, G., Faccini, M., Agnello, M., Senatore, F., Verweij, P., Fritzell, B., & Podda, A. (1999) · Vaccine · doi:10.1016/s0264-410x(99)00138-3 · Cited by 184
Evaluation of RTS,S/AS02A and RTS,S/AS01B in Adults in a High Malaria Transmission Area
Polhemus, M. E., Remich, S. A., Ogutu, B. R., Waitumbi, J. N., Otieno, L., Apollo, S., Cummings, J. F., Kester, K. E., Ockenhouse, C. F., Stewart, A., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006465 · Cited by 161
Baras, B., Stittelaar, K. J., Simon, J. H., Thoolen, R. J. M. M., Mossman, S. P., Pistoor, F. H. M., van Amerongen, G., Wettendorff, M. A., Hanon, E., & Osterhaus, A. D. M. E. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001401 · Cited by 156
Verstraeten, T., Descamps, D., David, M., Zahaf, T., Hardt, K., Izurieta, P., Dubin, G. O., & Breuer, T. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.09.049 · Cited by 155
Saponin-adjuvanted particulate vaccines for clinical use
Skene, C. D., & SUTTON, P. R. N. (2006) · Methods · doi:10.1016/j.ymeth.2006.05.019 · Cited by 153
Immunogenicity and protectivity of a new liposomal hepatitis A vaccine
Ambrosch, F., Wiedermann, G., Jonas, S., Althaus, B., Finkel, B., Glück, R., & Herzog, C. (1997) · Vaccine · doi:10.1016/s0264-410x(97)00015-7 · Cited by 152
Leroux‐Roels, I., Bernhard, R., Gerard, P. P., Dramé, M., Hanon, E., & Leroux-Roels, G. G. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001665 · Cited by 151
Self-citationLeffers, N., Lambeck, A. J. A., Gooden, M. J. M., Hoogeboom, B., Wolf, R., Hamming, I. E., Hepkema, B. G., Willemse, P. H. B., Molmans, B. H. W., Hollema, H., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24597 · Cited by 142
GIUDICE, G., Hilbert, A., Bugarini, R., Minutello, A., POPOVA, O., Toneatto, D., Schöndorf, I., Borkowski, A., Rappuoli, R., & Podda, A. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.01.015 · Cited by 119
Verdecia, B. G., Neninger, E., de la Torre, A., Leonard, I., Martínez, R., Viada, C., González, G., Mazorra, Z., Lage, A., & Crombet, T. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1050 · Cited by 119
Garçon, N., Heppner, D. G., & Cohen, J. (2003) · Expert Review of Vaccines · doi:10.1586/14760584.2.2.231 · Cited by 118
Feyerabend, S., Stevanovic, S., Gouttefangeas, C., Wernet, D., Hennenlotter, J., Bedke, J., Dietz, K., Pascolo, S., Kuczyk, M., Rammensee, H., et al. (2009) · The Prostate · doi:10.1002/pros.20941 · Cited by 107
Stewart, V. A., McGrath, S. M., Walsh, D. S., Davis, S. L., Hess, A. S., Ware, L. A., Kester, K. E., Cummings, J. F., Burge, J. R., Voss, G., et al. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.06.033 · Cited by 102
Barve, M., Bender, J., Senzer, N., Cunningham, C., Greco, F. A., McCune, D., Steis, R., Khong, H., Richards, D., Stephenson, J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6462 · Cited by 100
Antigenically Distinct MF59-Adjuvanted Vaccine to Boost Immunity to H5N1
Stephenson, I., Nicholson, K. G., Höschler, K., Zambon, M. C. F. A., Hancock, K., DeVos, J. R., Katz, J. M., Praus, M., & Banzhoff, A. (2008) · New England Journal of Medicine · doi:10.1056/nejmc0805274 · Cited by 99
Rümke, H. C., Bayas, J. M., de Juanes, J. R., Caso, C., Richardus, J. H., Campins, M., Rombo, L., Duval, X., Романенко, В. В., Schwarz, T. F., et al. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.02.068 · Cited by 92
Plasmodium falciparum malaria vaccines in development
Vekemans, J., & Ballou, W. R. (2008) · Expert Review of Vaccines · doi:10.1586/14760584.7.2.223 · Cited by 89
Ruf, B., Colberg, K., Frick, M., & Preusche, A. (2004) · Infection · doi:10.1007/s15010-004-3204-z · Cited by 80
Kanra, G., Marchisio, P., Feiterna‐Sperling, C., Gaedicke, G., Lazar, H., Durrer, P., Kürsteiner, O., Herzog, C., Kara, A., & Principi, N. (2004) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-200404000-00005 · Cited by 72
A prophylactic hepatitis B vaccine with a novel adjuvant system
Thoelen, S., Clercq, N. D., & Tornieporth, N. (2001) · Vaccine · doi:10.1016/s0264-410x(00)00462-x · Cited by 71
Immunostimulatory DNA as a vaccine adjuvant
Higgins, D., Marshall, J. D., Traquina, P., Nest, G. V., & Livingston, B. D. (2007) · Expert Review of Vaccines · doi:10.1586/14760584.6.5.747 · Cited by 71
Baldo, V., Baldovin, T., Floreani, A., Carraro, A. M., & Trivello, R. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.02.045 · Cited by 67
Current status and progress of prepandemic and pandemic influenza vaccine development
Leroux‐Roels, I., & Leroux-Roels, G. G. (2009) · Expert Review of Vaccines · doi:10.1586/erv.09.15 · Cited by 66
Self-citationAntibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly
Bruijn, I. D., Meyer, I., Gerez, L., Nauta, J. J. P., Giezeman‐Smits, K. M., & Palache, B. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.10.051 · Cited by 65
Schaad, U. B., Bühlmann, U., Burger, R., Rüdeberg, A., Wilder‐Smith, A., Rutishauser, M., Sennhauser, F. H., Herzog, C., Zellmeyer, M., & Glück, R. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.5.1163-1167.2000 · Cited by 64
de Bruijn, I. A., Nauta, J. J. P., Gerez, L., & Palache, A. M. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.05.035 · Cited by 62
Brichard, V. G., & Lejeune, D. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.7.951 · Cited by 62
Ben‐Yehuda, A., Joseph, A., Barenholz, Y., Zeira, E., Even‐Chen, S., Louria‐Hayon, I., Babai, I., Zakay‐Rones, Z., Greenbaum, E., Galprin, I., et al. (2003) · Vaccine · doi:10.1016/s0264-410x(03)00251-2 · Cited by 57
TLR7 imidazoquinoline ligand 3M-019 is a potent adjuvant for pure protein prototype vaccines
Johnston, D., Zaidi, B., & Bystryn, J. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0262-3 · Cited by 51
Middleton, D., Rockman, S. P., Pearse, M. J., Barr, I., Lowther, S., Klippel, J., Ryan, D., & Brown, L. E. (2009) · Journal of Virology · doi:10.1128/jvi.00241-09 · Cited by 51
Development of an Adjuvant to Enhance the Immune Response to Influenza Vaccine in the Elderly
Martin, J. (1997) · Biologicals · doi:10.1006/biol.1997.0086 · Cited by 45
Ben‐Yehuda, A., Joseph, A., Zeira, E., Even‐Chen, S., Louria‐Hayon, I., Babai, I., Zakay‐Rones, Z., Greenbaum, E., Barenholz, Y., & Kedar, E. (2003) · Journal of Medical Virology · doi:10.1002/jmv.10345 · Cited by 44
Baldo, V., Baldovin, T., Floreani, A., Fragapane, E., Trivello, R., & The Family Medicine Group (2007) · Journal of Clinical Immunology · doi:10.1007/s10875-007-9100-4 · Cited by 43
Malaria vaccines in development
Ballou, W. R. (2005) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.10.3.489 · Cited by 33
Rapid Antibody Response after Vaccination with a Virosomal Hepatitis A Vaccine
Ambrosch, F., Finkel, B., Herzog, C., Koren, A., & Kollaritsch, H. (2004) · Infection · doi:10.1007/s15010-004-3147-4 · Cited by 21
VII International Symposium on Respiratory Viral Infections
Bermingham, A., Henrickson, K. J., Hayden, F. G., & Zambon, M. C. F. A. (2007) · Antiviral Therapy · doi:10.1177/135965350701200s09.1 · Cited by 17
Cited by
Bio-inspired, bioengineered and biomimetic drug delivery carriers
Yoo, J.-W., Irvine, D. J., Discher, D. E., & Mitragotri, S. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3499 · Cited by 1,236
Vaccine Adjuvants: from 1920 to 2015 and Beyond
Pasquale, A., Preiss, S., Silva, F., & Garçon, N. (2015) · Vaccines · doi:10.3390/vaccines3020320 · Cited by 648
mRNA vaccine delivery using lipid nanoparticles
Reichmuth, A. M., Oberli, M. A., Jaklenec, A., Langer, R., & Blankschtein, D. (2016) · Therapeutic Delivery · doi:10.4155/tde-2016-0006 · Cited by 624
Liposomes as vaccine delivery systems: a review of the recent advances
Schwendener, R. A. (2014) · Therapeutic Advances in Vaccines · doi:10.1177/2051013614541440 · Cited by 525
The how’s and what’s of vaccine reactogenicity
Hervé, C., Laupèze, B., Del Giudice, G., Didierlaurent, A. M., & Tavares Da Silva, F. (2019) · npj Vaccines · doi:10.1038/s41541-019-0132-6 · Cited by 513
Metadata
- Authors
- Leroux-Roels, G.
- Venue
- Vaccine
- Publisher
- Elsevier BV
- Published
- 2010-08
- Volume
- 28
- Pages
- C25-C36
- ISSN
- 0264-410X (ISSN-L)
- OpenAlex
- W161788270
- Cited by
- 304
- References
- 77
- FWCI
- 8.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.